drugset / Trial / NCT01201161

Ranibizumab for Diabetic Traction Retinal Detachment

NCT01201161

Phase 2 Completed 19 enrolled University of Sao Paulo
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to assess the effect of ranibizumab in reducing intraoperative vitreous haemorrhage during pars plana vitrectomy, thus facilitating surgery and improving its anatomical and functional results in patients with advanced proliferative diabetic retinopathy and traction retinal detachment.

Timeline

Start
2008-12
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal